Founded in 1999 in South Korea, Genexine has a strong presence in China and invests in startups in the biotechnology and pharmaceutical fields. They typically invest in early-stage startups that are less than one year old. Some of their notable portfolio startups include I-Mab Biopharma. Genexine usually participates in investment rounds with three other partners, often including C-Bridge Capital. They have been active since 1999 and have a track record of investing in deals worth over $100 million.